ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag clinical trials evolution neuroscience

Haydeh Payami is wearing a purple dress and an orange and pink scarf and standing in front of a whiteboard.
A Microbial Link to Parkinson’s Disease
Mariella Bodemeier Loayza Careaga, PhD | Dec 4, 2023 | 6 min read
Haydeh Payami helped uncover the genetic basis of Parkinson’s disease. Now, she hopes to find new ways to treat the disease by studying the gut microbiome.
Can Viruses in the Genome Cause Disease?
Katarina Zimmer | Jan 1, 2019 | 10+ min read
Clinical trials that target human endogenous retroviruses to treat multiple sclerosis, ALS, and other ailments are underway, but many questions remain about how these sequences may disrupt our biology.
3D multicolored conceptual image representing hallucinogens and the human brain.
Natural High: Endogenous Psychedelics in the Gut and Brain
Iris Kulbatski, PhD | Sep 8, 2023 | 8 min read
Psychedelics are evolutionarily ancient compounds produced by fungi, plants, and microbes. Humans also synthesize psychedelics. Researchers want to know how and why.
Conceptual image showing molecules making up a brain shape
The Noncoding Regulators of the Brain
Christie Wilcox, PhD | Sep 12, 2022 | 10+ min read
Noncoding RNAs are proving to be critical players in the evolution of brain anatomy and cognitive complexity.
Nerve cell labelled with different colours
Psychedelics Slip Past Cell Membranes When Treating Depression
Alejandra Manjarrez, PhD | Feb 24, 2023 | 4 min read
The antidepressant properties of hallucinogenic drugs may stem from their ability to bind to intracellular serotonin receptors, a study suggests.
Image of someone scratching their skin.
A Chronic Itch: Burrowing Beneath the Skin
Brian S. Kim, MD | Sep 8, 2023 | 9 min read
We have barely scratched the surface of itch science and what it indicates about our health.
Optogenetic Therapies Move Closer to Clinical Use
Shawna Williams | Nov 16, 2017 | 6 min read
With a clinical trial underway to restore vision optogenetically, researchers also see promise in using the technique to treat deafness, pain, and other conditions.
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Cancer cell
Interrogating the Complexities of the Tumor Microenvironment
Alison Halliday, PhD, Technology Networks | May 19, 2023 | 5 min read
Gaining a better understanding of the dynamic and reciprocal interactions between cancer cells and the tumor microenvironment is essential for improving patient diagnosis and treatment.

Run a Search

ADVERTISEMENT